Reactions to Pew’s Scientific Roadmap for Antibiotic Discovery

Drugs© iStockphoto

Leading scientists, government officials, and others have echoed the need for new effective antibiotics.

On May 11, The Pew Charitable Trusts released a strategy aimed at overcoming the 30-year drought in the discovery of new types of antibiotics. The Scientific Roadmap for Antibiotic Discovery identifies priority research goals and provides a detailed plan to advance antibiotic discovery efforts in the public and private sectors. The proposal builds on the efforts of a scientific working group and was developed with input from a wide range of experts in industry and academia. Leading scientists, government officials, and others have echoed the need for such an initiative:

"We need to do more than increase efforts to discover and develop new antibiotics. We need a coordinated, targeted approach to tackling key scientific barriers, and fresh new ways to overcome antibiotic resistance. We need to attract a new generation of Alexander Flemings."

Eric S. Lander, Ph.D., president and founding director of the Broad Institute of MIT and Harvard and co-chair of the President’s Council of Advisors on Science and Technology

"Antimicrobial resistance poses a catastrophic threat to our health, and it is imperative that countries across the world work together to develop more lifesaving drugs. I welcome Pew’s new research on this subject, and I hope it inspires a ripple effect across the globe. Antimicrobial resistance must be high on the global agenda if we are to save modern medicine as we know it."

Professor Dame Sally Davies, chief medical officer for England

"As well as being a commercially troubled field, antibiotic research and development also faces some very significant scientific and technical challenges. If we are to properly reinvigorate antibiotic discovery, then we need to tackle these technical and commercial challenges in parallel, in a coordinated and focused way. This new roadmap is therefore key to filling important gaps in our scientific understanding about how to beat drug-resistant bacteria, and to supporting antibiotic discovery and development now and in the future."

Lord Jim O’Neill, chairman of the U.K. prime minister’s Review on Antimicrobial Resistance

"Antibacterial research and development is notoriously challenging. As outlined in Pew’s roadmap, we need to significantly expand the early science foundation for antibacterial discovery to improve both the success of traditional approaches and to explore and validate entirely new ‘alternative’ approaches for tackling this global unmet need."

David Payne, Ph.D., vice president, Anti-Bacterial Discovery Performance Unit, GlaxoSmithKline

"The Infectious Diseases Society of America [IDSA] has partnered with The Pew Charitable Trusts on multiple projects to stimulate the research and development of urgently needed new antibiotics to treat serious or life-threatening infections caused by multidrug-resistant pathogens. Our members are involved in both direct care of patients with complicated infections and in R&D of new lifesaving antibiotics. We need a robust, diverse antibiotic pipeline to address current and future threats, and this report is a vital tool to help us achieve that goal.”

Johan S. Bakken, M.D., Ph.D., F.I.D.S.A., president, IDSA

"Innovation in the field of antibacterials is essential in order to avoid a post-antibiotic era. Through the combined effects of major scientific challenges and chronic underspending, innovation in antibacterials is lagging behind that seen in other drug discovery areas. Successful implementation of Pew’s roadmap will have both short- and long-term positive impact on the discovery and development of new antimicrobials. But even more immediately, implementation of the roadmap provides a platform from which innovation can be rekindled and a forum for engagement from which, I am confident, new lines of innovation, presently unforeseen, will emerge."

Manos Perros, Ph.D., president and CEO, Entasis Therapeutics

"As a physician, I have seen all too often the human toll of antibiotic resistance. Bacteria have evolved to combat the antibiotics we have today at an alarming rate—and resistance is spreading. We need new drugs to protect our patients from new and increasingly dangerous infections. Pew’s roadmap outlines a directed approach to target the key scientific barriers to finding urgently needed antibiotics for the patients who need them."

William Schaffner, M.D., professor of preventive medicine, department of health policy, Vanderbilt University School of Medicine

"There is an urgent need for new effective antibiotics, in particular for Gram-negative bacteria. Currently we rely on a small number of active molecules and for all of them natural resistance mechanisms have been detected. ... Pew’s Scientific Roadmap for Antibiotic Discovery is a transformational research effort that complements Translocation’s work, and fills a gap in the global research landscape for antibiotic discovery."

Mathias Winterhalter, professor of biophysics at Jacobs University in Bremen, Germany, on behalf of the Innovative Medicines Initiative’s Translocation project

Report

A Scientific Roadmap for Antibiotics

A sustained and robust pipeline of new antibacterial drugs and therapies is critical to preserve public health

Quick View
Report

In recent decades, the discovery and development of new antibiotics have slowed dramatically as scientific barriers to drug discovery, regulatory challenges, and diminishing returns on investment have led major drug companies to scale back or abandon their antibiotic research.

Press Releases & Statements

Pew Releases Scientific Roadmap to Spur Antibiotic Discovery and Innovation

Report proposes approach to end decades-long gap in new antibiotic approval

Quick View
Press Releases & Statements

The Pew Charitable Trusts today released a strategy to end the 30-year drought in the discovery of new types of antibiotics, key to fighting some of the most serious microbial threats. The Scientific Roadmap for Antibiotic Discovery identifies priority research goals and specific steps to break through the most significant scientific barriers impeding antibiotic discovery and to pave the way for urgently needed new drugs.

Project

Antibiotic Innovation

Quick View
Project

Antibiotic Innovation

Antibiotic-resistant bacteria pose an urgent and growing public health threat. The more we use existing antibiotics, the less effective these life-saving drugs become. Pew supports policies and research that spur the creation of new antibiotics to defeat resistant infections; ensure that antibiotics are prescribed for human use only when necessary; and reduce the need for antibiotics in food animals.

What Is Antibiotic Resistance—and How Can We Fight It?

Sign up for our four-week email series The Race Against Resistance.

Quick View

Antibiotic-resistant bacteria, also known as “superbugs,” are a major threat to modern medicine. But how does resistance work, and what can we do to slow the spread? Read personal stories, expert accounts, and more for the answers to those questions in our four-week email series: Slowing Superbugs.